Principal Financial Group Inc. Sells 9,340 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Principal Financial Group Inc. decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 4.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 192,947 shares of the company’s stock after selling 9,340 shares during the quarter. Principal Financial Group Inc. owned 0.57% of TransMedics Group worth $12,030,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group in the third quarter worth approximately $2,560,000. New York State Teachers Retirement System bought a new stake in TransMedics Group during the third quarter worth $1,217,000. Farther Finance Advisors LLC raised its position in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in TransMedics Group by 48.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company’s stock valued at $1,407,000 after acquiring an additional 2,916 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in TransMedics Group by 777.4% during the 3rd quarter. Amalgamated Bank now owns 9,774 shares of the company’s stock worth $1,535,000 after acquiring an additional 8,660 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $72.12 on Friday. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The business has a fifty day simple moving average of $67.52 and a two-hundred day simple moving average of $102.22. The company has a market capitalization of $2.42 billion, a P/E ratio of 76.72 and a beta of 2.12.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.00% of the stock is currently owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.